Hitto Kaufmann
Chief Tech/Sci/R&D Officer chez PIERIS PHARMACEUTICALS, INC.
Fortune : - $ au 29/02/2024
Profil
Currently, Hitto Kaufmann is Chief Scientific Officer of Hansa Biopharma AB and Chief Scientific Officer & Senior Vice President at Pieris Pharmaceuticals, Inc., Co-Managing Director at Pieris Pharmaceuticals GmbH (a subsidiary of Pieris Pharmaceuticals, Inc.).
Hitto Kaufmann is also on the board of European Society For Animal Cell Technology.
Dr. Kaufmann previously occupied the position of Global Head-Strategy & Operations at Sanofi and Vice President-Process Science at Boehringer Ingelheim Corp.
He received a graduate degree from Technische Universität Braunschweig, a doctorate from Swiss Federal Institute of Technology and a graduate degree from The Scripps Research Institute.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
24/02/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Postes actifs de Hitto Kaufmann
Sociétés | Poste | Début |
---|---|---|
PIERIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 30/08/2019 |
HANSA BIOPHARMA AB | Chief Tech/Sci/R&D Officer | 01/12/2023 |
European Society For Animal Cell Technology | Director/Board Member | - |
Pieris Pharmaceuticals GmbH
Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Chief Executive Officer | - |
Anciens postes connus de Hitto Kaufmann
Sociétés | Poste | Fin |
---|---|---|
SANOFI | Chief Operating Officer | 02/01/2019 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | - |
Formation de Hitto Kaufmann
The Scripps Research Institute | Graduate Degree |
Swiss Federal Institute of Technology | Doctorate Degree |
Technische Universität Braunschweig | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
SANOFI | Health Technology |
HANSA BIOPHARMA AB | Health Technology |
PIERIS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Pieris Pharmaceuticals GmbH
Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Health Technology |
European Society For Animal Cell Technology |